Abstract
Corporates face biotech revolution. Big corporations account for an increasingly large share of the R&D budget as regards biotechnologies. Their own constraints would seem to have led them to slow down rather than accelerate the applications of these new techniques. This could continue to be the case as long as the "Fordist" options that until now have influenced agricultural growth have not been called into question. The new research options could thereafter allow for a gradual change in the prédominant technological paradigms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
